A new antibody treatment reduced levels of type I interferon-producing cells in patients with cutaneous lupus, improving skin symptoms during phase 1 clinical trials.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes.